A Research Guide for
Ulcers

Helicobacter pylori is a spiral-shaped bacterium that burrows into the stomach’s protective mucous layer and survives in the acidic environment. It was discovered in 1982 by Barry Marshall and Robin Warren — a discovery so important it earned the 2005 Nobel Prize in Medicine. Before this, ulcers were blamed on stress and spicy food, and treatment meant a lifetime of acid-suppressing medication or surgery.

H. pylori infects approximately 35–40% of the US population, though most carriers never develop ulcers. The bacterium weakens the stomach’s protective mucous barrier, allowing stomach acid to damage the underlying tissue. This causes approximately 60–70% of gastric ulcers and 80–90% of duodenal ulcers.

Non-steroidal anti-inflammatory drugs (NSAIDs) — including ibuprofen, naproxen, and aspirin — are the second major cause. They inhibit cyclooxygenase (COX) enzymes, reducing production of prostaglandins that protect the stomach lining. About 15–30% of regular NSAID users develop ulcers visible on endoscopy, and NSAID-related GI complications cause approximately 16,500 deaths annually in the US (historical estimate from 1990s data; rates have declined with modern prevention strategies).

Less common causes include Zollinger-Ellison syndrome (a tumor that produces excessive gastric acid), stress ulcers in critically ill patients, medications (bisphosphonates, potassium chloride, certain chemotherapy drugs), and Crohn’s disease.

Venous leg ulcers (VLUs) account for about 70% of all chronic leg ulcers. They form because of venous insufficiency — a condition where the one-way valves in leg veins become damaged, allowing blood to flow backward and pool in the lower legs. This increased pressure (venous hypertension) damages the tiny blood vessels in the skin, causing inflammation, fluid leakage, skin changes, and eventually tissue breakdown.

VLUs typically appear in the “gaiter area” — the lower leg between the ankle and mid-calf. They are often shallow, irregularly shaped, with a moist wound bed, and surrounded by characteristic skin changes: brown discoloration (hemosiderin staining), hardened skin (lipodermatosclerosis), and sometimes eczema-like changes. They tend to be mildly painful, especially at the end of the day or when legs are dependent.

Risk factors include prior deep vein thrombosis (DVT), varicose veins, obesity, prolonged standing, multiple pregnancies, and older age. VLUs affect about 1% of adults at some point in their lives, with recurrence rates of 50–70% without ongoing compression.

Diabetic foot ulcers (DFUs) represent one of the most feared complications of diabetes. Approximately 19–34% of people with diabetes will develop a foot ulcer during their lifetime (per Armstrong 2017), and DFUs precede approximately 85% of diabetes-related amputations. The annual incidence is about 2–5% among all diabetic patients.

DFUs result from a combination of three factors:

• Peripheral neuropathy: Diabetes damages nerves in the feet, causing loss of sensation. Patients cannot feel blisters, cuts, or pressure points, so injuries go unnoticed and worsen.
• Peripheral arterial disease (PAD): Diabetes accelerates atherosclerosis in leg arteries, reducing blood flow needed for healing. Up to 50% of DFU patients have significant PAD.
• Foot deformity and altered biomechanics: Neuropathy causes muscle wasting and altered foot shape, creating abnormal pressure points where ulcers form.

The typical DFU occurs on the plantar (bottom) surface of the foot over a bony prominence, often painless due to neuropathy. The patient may not notice the wound until it becomes infected or is found during a foot exam. This is why daily foot checks are critical for people with diabetes.

Pressure injuries (formerly called pressure ulcers, bedsores, or decubitus ulcers) form when sustained pressure on the skin compresses blood vessels, cutting off oxygen and nutrients to the tissue. They occur most commonly over bony prominences — the sacrum (tailbone), heels, hips, shoulder blades, and back of the head.

People at highest risk are those who cannot reposition themselves independently: patients with spinal cord injuries, stroke survivors, those in intensive care, frail elderly individuals, and anyone confined to a bed or wheelchair for extended periods. Additional risk factors include malnutrition, incontinence, diabetes, and reduced consciousness.

Pressure injuries are classified by depth in stages 1 through 4, with two additional categories (unstageable and deep tissue pressure injury). Stage 1 is intact but reddened skin; Stage 4 involves exposure of bone, tendon, or muscle. Hospital-acquired pressure injuries (HAPIs) are now considered “never events” by many healthcare systems — meaning they are viewed as preventable with proper care.

Arterial ulcers occur when peripheral artery disease severely reduces blood flow to the legs and feet. They tend to appear on the toes, foot, or shin; are often painful (especially at night or when legs are elevated); have a “punched out” appearance with pale or necrotic wound beds; and are surrounded by thin, shiny, hairless skin. Treatment requires restoring blood flow through revascularization (angioplasty, stenting, or bypass surgery). Compression is contraindicated in pure arterial ulcers.

Oral and mouth ulcers include aphthous ulcers (canker sores, the most common type), herpetic ulcers (cold sores caused by herpes simplex virus), and ulcers associated with systemic diseases like Behçet’s disease, Crohn’s disease, or oral cancer. Most aphthous ulcers heal on their own within 1–2 weeks; persistent or recurrent ulcers warrant medical evaluation.

Rare ulcer syndromes include pyoderma gangrenosum (an autoimmune condition causing rapidly enlarging, painful ulcers), Marjolin’s ulcer (malignant transformation of chronic wounds), and calciphylaxis (painful skin necrosis in patients with kidney disease).

Testing for H. pylori is essential for anyone diagnosed with a peptic ulcer. Several testing methods are available:

• Urea breath test (UBT): You drink a solution containing urea labeled with carbon-13 or carbon-14, then breathe into a collection device. If H. pylori is present, it breaks down the urea, and the labeled carbon is detected in your breath. Accuracy: >95%. This is the preferred non-invasive test for both initial diagnosis and confirming eradication after treatment.
• Stool antigen test: A stool sample is analyzed for H. pylori proteins. Accuracy: >95% when using monoclonal antibody-based tests. Convenient and widely available. Also good for confirming eradication.
• Blood antibody test: Detects antibodies to H. pylori in the blood. Limitation: antibodies persist for months after eradication, so this test cannot distinguish active from past infection. Not recommended for confirming cure.
• Endoscopy with biopsy: During upper endoscopy (EGD), the doctor can directly visualize the ulcer and take tissue samples for rapid urease test (CLO test), histology, and culture with susceptibility testing. This is the gold standard when endoscopy is needed anyway (for alarm symptoms, non-healing ulcers, or to rule out cancer).

Important: Stop PPIs at least 2 weeks and antibiotics at least 4 weeks before H. pylori testing (except blood antibody test). These medications can cause false-negative results. Vonoprazan may also need to be stopped — ask your doctor.

Upper endoscopy (esophagogastroduodenoscopy or EGD) is a procedure where a thin, flexible tube with a camera is passed through the mouth into the esophagus, stomach, and duodenum. It allows the doctor to directly see the ulcer, determine its size and severity, take biopsies (to test for H. pylori and rule out cancer), and treat active bleeding if present.

Endoscopy is typically recommended when:

• You have alarm features (weight loss, difficulty swallowing, persistent vomiting, anemia, GI bleeding)
• You are over age 60 with new upper GI symptoms
• Symptoms persist despite appropriate treatment
• A gastric ulcer was found (all gastric ulcers require biopsy to rule out malignancy)
• You have signs of GI bleeding

The procedure is usually done under sedation and takes 10–20 minutes. Most patients go home the same day.

One of the most important changes in ulcer management in 2024 is the emphasis on susceptibility-guided therapy for H. pylori. Antibiotic resistance has made standard triple therapy (PPI + clarithromycin + amoxicillin) unreliable — clarithromycin resistance now exceeds 20% in many US regions, meaning roughly 1 in 5 patients will have treatment failure with this regimen.

The ACG 2024 guidelines now recommend:

• Culture and susceptibility testing when endoscopy is performed (particularly after a first treatment failure)
• Molecular/PCR-based resistance testing (available via stool-based assays) as an emerging alternative to culture
• Choosing antibiotic regimens based on local resistance patterns when individual susceptibility data is unavailable

If susceptibility testing is not available, the guidelines recommend avoiding clarithromycin-based triple therapy in regions with >15% clarithromycin resistance. For first treatment when antibiotic resistance is unknown, guidelines now recommend bismuth quadruple therapy (4-drug combination) for 14 days as the preferred approach. Vonoprazan-amoxicillin dual therapy and rifabutin triple therapy (Talicia) are effective alternatives recommended by the ACG 2024 guidelines.

Vonoprazan is an FDA-approved potassium-competitive acid blocker (P-CAB) that represents a significant advance over traditional proton pump inhibitors (PPIs). Key differences:

• Faster onset: Vonoprazan achieves full acid suppression within hours of the first dose. PPIs typically take 2–3 days of repeated dosing to reach maximum effect.
• More potent acid suppression: Vonoprazan maintains stomach pH above 4 for a greater percentage of the day compared to PPIs.
• Not affected by CYP2C19 metabolism: PPI effectiveness varies significantly based on your genetic CYP2C19 metabolizer status (about 2–15% of the population are “rapid metabolizers” who break down PPIs too fast). Vonoprazan has consistent efficacy regardless of CYP2C19 status.
• Better H. pylori eradication: In clinical trials, vonoprazan-based triple therapy achieved about 81–85% cure rates overall, with better results than older PPI-based triple therapy (about 69%). Results vary based on antibiotic resistance patterns. In clarithromycin-resistant infections, the advantage was even larger.

Vonoprazan is approved in the US as part of combination packs (Voquezna Triple Pak and Voquezna Dual Pak) for H. pylori eradication. It was first developed and used in Japan (as Takecab) since 2015, with extensive real-world data supporting its efficacy and safety.

Cost consideration: Vonoprazan is currently more expensive than generic PPIs. Insurance coverage varies. Ask your doctor and pharmacist about coverage, patient assistance programs, and whether the benefits justify the cost in your specific situation.

If you test positive for H. pylori, you will be prescribed a multi-drug regimen for 14 days. Common regimens include:

• Bismuth quadruple therapy (BQT): PPI + bismuth subsalicylate + metronidazole + tetracycline (14 days). The ACG 2024 preferred first-line approach when antibiotic resistance is unknown. Effective regardless of clarithromycin resistance. Eradication rate: ~85–90%. Four pills four times daily — complex but effective.
• Vonoprazan-amoxicillin dual therapy: Vonoprazan + high-dose amoxicillin (14 days). Avoids clarithromycin entirely. An effective ACG 2024 recommended alternative. Eradication rate: ~78–84%.
• Rifabutin triple therapy (Talicia): Rifabutin + amoxicillin + omeprazole (14 days). FDA-approved first-line option. Effective against clarithromycin-resistant and metronidazole-resistant H. pylori. An ACG 2024 recommended alternative.
• Vonoprazan-based triple therapy: Vonoprazan + amoxicillin + clarithromycin (14 days). A newer, effective option when clarithromycin susceptibility is confirmed. In clinical trials, achieved about 81–85% cure rates overall, with better results than older PPI-based triple therapy (about 69%). Results vary based on antibiotic resistance patterns. Note: Vonoprazan triple therapy still contains clarithromycin — it works better than older PPI combinations, but can still fail if the bacteria are resistant to clarithromycin. Ask your doctor if resistance testing is available.
• PPI-based triple therapy: PPI + clarithromycin + amoxicillin (or metronidazole) for 14 days. Now only recommended where clarithromycin resistance is <15% and susceptibility is confirmed. Eradication rate: ~70–85% depending on resistance.
• PPI-based concomitant therapy: PPI + clarithromycin + amoxicillin + metronidazole (14 days). Higher eradication rate than triple therapy due to dual antibiotic coverage.

Critical points:

• Take all medications exactly as prescribed for the full 14 days — stopping early breeds antibiotic resistance
• Confirm eradication with a urea breath test or stool antigen test at least 4 weeks after completing treatment
• If first-line treatment fails, second-line therapy should be guided by susceptibility testing whenever possible

PPIs remain the most widely used medications for peptic ulcer healing. They work by irreversibly blocking the proton pump (H+/K+ ATPase) in stomach lining cells, reducing acid production by up to 90%. Common PPIs include:

• Omeprazole (Prilosec) — the original, available over-the-counter
• Esomeprazole (Nexium)
• Pantoprazole (Protonix)
• Lansoprazole (Prevacid)
• Rabeprazole (AcipHex)
• Dexlansoprazole (Dexilant)

For ulcer healing, PPIs are typically taken once daily (before breakfast) for 4–8 weeks. Duodenal ulcers often heal in 4 weeks; gastric ulcers may need 8–12 weeks.

Long-term PPI use: While PPIs are safe for most people during ulcer healing, prolonged use (>1 year) has been associated with potential risks including vitamin B12 deficiency, magnesium deficiency, increased fracture risk, C. difficile infection, and chronic kidney disease. These risks are generally small and must be weighed against the benefit. If you need long-term acid suppression, discuss the lowest effective dose with your doctor.

If your ulcer is caused by NSAIDs, the most important step is to stop or replace the NSAID if possible:

• Best option: Switch to acetaminophen (Tylenol) for pain, which does not damage the stomach lining
• If you must continue NSAIDs: Take the lowest effective dose for the shortest duration, and add a daily PPI for gastroprotection
• COX-2 selective NSAIDs (celecoxib/Celebrex) cause fewer GI complications than traditional NSAIDs, but are not risk-free, especially combined with aspirin
• Low-dose aspirin for cardiovascular protection: do not stop without discussing with your cardiologist. Add a PPI if you have ulcer risk factors

Important: Do not stop aspirin prescribed for heart disease without talking to your cardiologist first.

High-risk patients who need NSAIDs (prior ulcer history, older age, concurrent anticoagulants or corticosteroids) should always take a PPI while using any NSAID, including aspirin. Misoprostol is an alternative gastroprotective agent but causes diarrhea in many patients.

When a peptic ulcer bleeds, endoscopy is both diagnostic and therapeutic. The gastroenterologist can identify the bleeding source and treat it during the same procedure using techniques such as:

• Epinephrine injection: Injected around the bleeding vessel to constrict it and slow bleeding (always combined with another method)
• Thermal coagulation: A heated probe or bipolar electrode cauterizes the bleeding vessel
• Hemostatic clips: Metal clips are placed directly on the bleeding vessel to mechanically stop the bleed
• Hemospray: A topical hemostatic powder sprayed over a diffusely bleeding surface — newer but increasingly used as a temporizing measure

After successful endoscopic treatment, high-dose intravenous PPI therapy is usually given for 72 hours, followed by oral PPI therapy. If bleeding cannot be controlled endoscopically, angiographic embolization (blocking the artery feeding the ulcer via a catheter) or surgery may be needed.

Esophageal ulcers most commonly result from gastroesophageal reflux disease (GERD), but can also be caused by medications (particularly bisphosphonates taken improperly, potassium chloride, and certain antibiotics), infections (Candida, herpes, CMV — especially in immunocompromised patients), and caustic ingestion. Treatment targets the underlying cause plus PPI therapy.

Stress ulcers occur in critically ill patients (ICU, major burns, head injuries) due to compromised mucosal blood flow. Cushing ulcers (associated with brain injury) and Curling ulcers (associated with severe burns) are named subtypes. Prevention with acid suppression in high-risk ICU patients is standard practice.

Zollinger-Ellison syndrome is caused by a gastrin-secreting tumor (gastrinoma) that produces massive amounts of stomach acid, causing severe, multiple, or refractory peptic ulcers. Treatment involves high-dose PPIs to control acid, tumor localization, and surgical resection when possible.

Diagnosis is primarily clinical (based on appearance, location, and medical history), but vascular testing is essential to confirm venous disease and rule out arterial involvement:

• Ankle-Brachial Index (ABI): A quick, non-invasive test comparing blood pressure in the ankle to the arm. ABI ≥0.8 generally indicates safe arterial blood flow and confirms that compression can be applied safely. ABI <0.5 suggests significant arterial disease — compression may be contraindicated.
• Duplex ultrasound: The gold standard for assessing venous insufficiency. It identifies which veins have reflux (backward flow), detects prior DVT, and maps venous anatomy for potential surgical intervention.
• Clinical features: Typical VLU location (medial gaiter area), surrounding skin changes (brown hemosiderin staining, lipodermatosclerosis, varicose eczema), shallow wound bed with granulation tissue, moderate exudate, mild to moderate pain.

Compression is the single most important treatment for venous leg ulcers. It works by counteracting venous hypertension, improving blood flow back to the heart, reducing edema, and creating an environment that promotes healing. Without compression, venous ulcers heal slowly or not at all, and recurrence is almost guaranteed.

Types of compression:

• Multi-component bandaging: The gold standard during active healing. Systems like Profore (4-layer) or Coban 2-Layer provide sustained therapeutic compression (~40 mmHg at the ankle). These are typically applied by a nurse weekly at dressing changes.
• Compression stockings: Used after healing to prevent recurrence. Typically Class 2 (23–32 mmHg) or Class 3 (34–46 mmHg). Must be worn every day for life to prevent ulcer recurrence.
• Adjustable compression wraps (Velcro systems): Such as CircAid or ReadyWrap. Easier for patients to apply themselves, especially those with limited hand dexterity or who live alone.
• Intermittent pneumatic compression (IPC): Inflatable boots that cyclically compress the legs. Used in addition to bandaging for patients with very slow healing or immobility.

Key points:

• Compression must be applied correctly to be effective and safe — trained professionals should apply initial bandaging
• ABI must be checked before starting compression to rule out arterial disease
• Some discomfort is normal initially; severe pain, numbness, or color change means the compression is too tight — remove it immediately
• With high-quality multilayer compression and appropriate care, healing rates of 60–75% are typical at 24 weeks, reaching 85%+ when combined with early vein ablation (EVRA trial)

The EVRA (Early Venous Reflux Ablation) trial, published in the New England Journal of Medicine, demonstrated that early endovenous ablation of superficial venous reflux — within 2 weeks of referral — combined with compression therapy, significantly improved healing rates and reduced ulcer recurrence compared to compression alone.

Endovenous ablation is a minimally invasive procedure performed under local anesthesia that destroys the faulty vein from the inside using heat (radiofrequency or laser) or medical adhesive (cyanoacrylate glue). The procedure takes approximately 30–60 minutes, and patients walk out the same day.

Who should be considered: Any patient with a venous leg ulcer who has superficial venous reflux on duplex ultrasound should be assessed for early endovenous ablation. NICE guidelines now recommend referral within 2 weeks for VLU patients with confirmed superficial reflux.

Access reality: Not all wound care centers have direct relationships with vascular surgeons who perform ablation. If your wound care team has not discussed this option, ask about referral to a vascular specialist.

The IWGDF 2023 guidelines are unequivocal: offloading is the most critical intervention for plantar (bottom of foot) diabetic foot ulcers. Without proper offloading, no dressing, growth factor, or advanced therapy will heal the wound.

Offloading devices ranked by evidence:

• Total contact cast (TCC): The gold standard. A custom-molded cast that redistributes pressure away from the ulcer and cannot be removed by the patient (ensuring adherence). Healing rates with TCC are approximately 73–100% in 6–12 weeks.
• Irremovable knee-high walker: A prefabricated walker made irremovable by wrapping it in cohesive bandage or a fiberglass strip. Nearly as effective as TCC and easier to apply. IWGDF strongly recommends this as an alternative.
• Removable knee-high walker: Same device without being made irremovable. Less effective because adherence drops — patients remove the device and walk on the wound. Only recommended when irremovable options are truly contraindicated.
• Therapeutic footwear and insoles: Custom-molded shoes for healed ulcers to prevent recurrence, not adequate for active ulcer offloading.

The offloading gap: Despite overwhelming evidence, studies show that only 6–20% of DFU patients receive adequate offloading (TCC or irremovable walker). This is one of the greatest missed opportunities in wound care. If your wound care provider has not addressed offloading, raise it yourself.

For DFUs that do not show at least 50% size reduction in 4 weeks with standard care (offloading + appropriate dressings + blood sugar control), advanced therapies should be considered:

• Sucrose octasulfate dressings (UrgoStart): A specialized dressing containing sucrose octasulfate that inhibits matrix metalloproteinases (enzymes that break down healing tissue). RCT evidence (Explorer trial) showed significantly improved healing in neuroischemic DFUs compared to standard dressings. IWGDF 2023 conditionally recommends for non-healing neuroischemic ulcers.
• Dehydrated human amnion/chorion membrane (dHACM/EpiFix): A processed human placental tissue containing growth factors that promote healing. Multiple RCTs show improved complete wound closure rates compared to standard care. Applied weekly at wound care visits.
• Fish skin grafts (Kerecis Omega3 Wound): Acellular fish skin (Atlantic cod) that serves as a wound matrix scaffold. Contains omega-3 fatty acids with anti-inflammatory properties. RCT data shows improved healing for chronic DFUs.
• Negative pressure wound therapy (NPWT/VAC): A sealed dressing connected to a vacuum pump that removes wound fluid, promotes blood flow, and stimulates granulation tissue. Particularly useful for deep wounds and post-surgical wounds.
• Hyperbaric oxygen therapy (HBOT): Breathing 100% oxygen in a pressurized chamber increases oxygen delivery to the wound. Evidence supports use in select DFUs with ischemia that are not candidates for revascularization. IWGDF 2023 provides a conditional recommendation for specific cases.

Access note: Advanced wound therapies vary significantly in availability and insurance coverage. Many require referral to specialized wound care centers. Not all wound centers offer all options. Ask your team what is available and covered.

Blood sugar control is fundamental to DFU healing and prevention. The key targets:

• HbA1c <7% is the general target for DFU prevention. Every 1% reduction in HbA1c reduces complication risk significantly.
• During active wound healing: Avoid both hyperglycemia (which impairs immune function and wound healing) and hypoglycemia (which can cause falls and further foot injuries).
• GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GIP/GLP-1 receptor agonist tirzepatide — newer diabetes medications that may have additional benefits for wound healing beyond glucose control. Emerging evidence suggests these medications may improve microvascular blood flow and reduce inflammation, though DFU-specific trial data is still being gathered.

The NPIAP/EPUAP/PPPIA 2019 classification system uses six categories:

• Stage 1: Intact skin with non-blanchable redness over a bony prominence. In darker skin tones, the area may appear different in color, temperature, or firmness compared to surrounding skin. This is the warning stage — pressure must be relieved immediately.
• Stage 2: Partial-thickness skin loss involving the epidermis and/or dermis. Appears as a shallow open ulcer with a red-pink wound bed, or an intact or open blister. No slough (dead tissue) visible.
• Stage 3: Full-thickness skin loss extending into subcutaneous fat. Bone, tendon, and muscle are not exposed. Slough may be present. Undermining and tunneling may occur.
• Stage 4: Full-thickness tissue loss with exposed bone, tendon, cartilage, or muscle. Slough or eschar (hard, dark dead tissue) is often present. High risk of osteomyelitis (bone infection).
• Unstageable: Full-thickness tissue loss with the wound base obscured by slough or eschar, making it impossible to determine the true depth until the dead tissue is removed.
• Deep tissue pressure injury (DTPI): Purple or maroon area of intact or disrupted skin, or blood-filled blister caused by damage to underlying soft tissue from pressure. May evolve rapidly to reveal a Stage 3 or 4 injury.

Most pressure injuries are preventable. Hospital-acquired pressure injuries (HAPIs) are classified as “never events” by many healthcare organizations. Key prevention strategies:

• Repositioning every 2 hours in bed, every 1 hour in a wheelchair. Use a clock schedule or alarm reminders.
• Pressure-redistributing support surfaces: Specialized mattresses (foam, alternating pressure, air-fluidized) distribute weight more evenly. Hospital beds and home care mattresses should be appropriate for the patient’s risk level.
• Prophylactic sacral dressings: Foam dressings (such as Mepilex Border Sacrum) applied over the sacrum before injury occurs reduce friction, shear, and moisture, significantly decreasing HAPI rates. Multiple clinical studies support this simple intervention.
• Skin care: Keep skin clean and dry. Use barrier creams for incontinence. Avoid aggressive rubbing. Moisturize dry skin.
• Nutrition: Adequate protein (1.25–1.5 g/kg/day), calories, and hydration support skin integrity. Supplements (oral nutritional drinks, vitamin C, zinc) may help in malnourished patients.
• Heel elevation: Heels should be “floated” off the bed using pillows or specialized heel suspension devices. Heel pressure injuries are extremely common and entirely preventable.

Arterial ulcers are caused by inadequate blood supply to the legs and feet due to peripheral artery disease (PAD). They differ significantly from venous ulcers:

• Appearance: Typically deep, “punched out,” with a pale, grey, or necrotic wound base. Little or no granulation tissue.
• Location: Toes, foot, lateral ankle, or over bony prominences on the lower leg.
• Pain: Often very painful, especially at night and when legs are elevated. Dangling feet over the bed edge may relieve pain (gravity helps blood flow).
• Surrounding skin: Thin, shiny, hairless, with absent or diminished pulses.

Treatment priorities:

• Vascular assessment (ABI, toe pressures, duplex ultrasound, CTA/MRA) to determine severity and revascularization options
• Revascularization (angioplasty/stenting or surgical bypass) to restore blood flow — without adequate blood flow, the ulcer cannot heal
• Risk factor management: smoking cessation (critical), statin therapy, blood pressure control, antiplatelet therapy, diabetes management
• Wound care focused on keeping the wound clean and dry (moist wound healing is less appropriate when blood supply is severely impaired)
• Compression is generally contraindicated in pure arterial ulcers — it can worsen ischemia

Dead tissue (necrotic tissue, slough, eschar) in a wound prevents healing and promotes infection. Debridement — removing this dead tissue — is a critical step in wound management. Methods include:

• Sharp/surgical debridement: A clinician uses a scalpel, scissors, or curette to physically cut away dead tissue. Fast and effective, but requires trained practitioners and may need local anesthesia.
• Autolytic debridement: Using moisture-retentive dressings (hydrogels, hydrocolloids) to soften and dissolve dead tissue using the body’s own enzymes. Slower but painless. Appropriate for smaller amounts of dead tissue.
• Enzymatic debridement: Applying enzyme-based ointments (collagenase/Santyl) that digest dead tissue while sparing healthy tissue. Applied at dressing changes. Requires a prescription.
• Biological (larval) debridement: Medical-grade maggot therapy using sterile fly larvae that selectively consume dead tissue and secrete antimicrobial substances. Effective but limited by patient acceptance. Used in select cases at specialized centers.
• Mechanical debridement: Wet-to-dry dressings (older method, now less preferred as it is non-selective and painful) or monofilament fiber pads. Low-frequency ultrasound debridement is a newer option.

Important exception: Stable, dry eschar on heels or digits with arterial insufficiency should generally not be debrided, as removing it may expose tissue that cannot heal. Let your wound care specialist make this judgment.

There are hundreds of wound dressings available. The basic principle: match the dressing to the wound’s needs.

• Foam dressings: Absorbent, comfortable, provide some cushioning. Good for moderate to heavy exudate. Examples: Mepilex, Allevyn.
• Alginate dressings: Made from seaweed fibers, highly absorbent. Good for heavily draining wounds. Form a gel when they absorb fluid. Examples: Kaltostat, Aquacel.
• Hydrocolloid dressings: Self-adhesive, waterproof, provide a moist environment for autolytic debridement. Good for light to moderate exudate and shallow wounds. Example: DuoDERM.
• Hydrogel dressings: Add moisture to dry wounds and promote autolytic debridement. Good for dry wounds and painful wounds (cooling effect). Examples: Intrasite Gel, Purilon.
• Antimicrobial dressings: Contain silver, iodine, honey (Medihoney), or PHMB (polyhexamethylene biguanide) to manage wound bioburden. Used when infection is present or wound is at high risk. Should be time-limited, not indefinite.
• Collagen dressings: Provide a scaffold for tissue repair. Used in stalled wounds that have clean wound beds but are not progressing.

Dressing selection and change frequency should be guided by your wound care nurse or specialist. “More expensive” does not always mean “better” — the right dressing is the one that matches your wound’s current needs.

Negative pressure wound therapy (also called VAC therapy) uses a sealed foam or gauze dressing connected to a vacuum pump that applies continuous or intermittent suction to the wound. Benefits include:

• Removes excess wound fluid and reduces edema
• Promotes blood flow to the wound edges
• Stimulates formation of granulation tissue
• Reduces wound size by drawing the edges together
• Reduces bacterial load in the wound

NPWT is commonly used for deep diabetic foot ulcers, post-surgical wounds, pressure injuries (Stage 3–4), and traumatic wounds. Portable devices (PICO, Prevena) allow outpatient use. Dressings are typically changed every 2–3 days.

Limitations: Not appropriate for wounds with active uncontrolled infection, exposed blood vessels, malignancy, or untreated osteomyelitis. The vacuum pump noise and need to carry the device can be inconvenient.

When standard wound care fails to achieve adequate healing (less than 50% size reduction in 4 weeks), advanced biological therapies may be considered:

• Cellular/tissue-based products (CTPs): Include dHACM (EpiFix), living skin equivalents (Apligraf, Dermagraft), and acellular dermal matrices. These provide growth factors, scaffolding, and in some cases living cells to stimulate wound repair.
• Fish skin grafts (Kerecis): Acellular Atlantic cod skin processed to maintain its structure and omega-3 fatty acid content. Applied to the wound as a biological scaffold. Multiple RCTs demonstrate improved healing for DFUs.
• Autologous skin grafts: Split-thickness skin grafts (STSGs) harvested from the patient’s own body (usually the thigh) and transplanted to the wound. Used for large or non-healing wounds when the wound bed is well-prepared.
• Platelet-rich plasma (PRP): Concentrated platelets from the patient’s own blood applied to the wound to deliver growth factors. Evidence is mixed; some studies show benefit for chronic wounds.

For arterial ulcers and diabetic foot ulcers with significant peripheral artery disease, restoring blood flow is essential for healing:

• Angioplasty and stenting: A minimally invasive procedure where a catheter with a balloon is inserted into the narrowed artery, inflated to open it, and often a metal stent is placed to keep it open. Can be performed below the knee and into the foot.
• Surgical bypass: A vein graft or synthetic graft is used to create a detour around the blocked artery. Used for longer or more complex blockages.
• Endovascular techniques: Drug-coated balloons and atherectomy (plaque removal) are newer approaches for specific anatomies.

The decision between endovascular (catheter-based) and surgical approaches depends on the location and extent of arterial disease, patient fitness for surgery, and local expertise. Often a vascular surgeon and interventional radiologist collaborate on the optimal approach.

As discussed in the venous leg ulcer section, early endovenous ablation treats the underlying venous reflux. Techniques include:

• Radiofrequency ablation (RFA): A catheter delivers radiofrequency energy to heat and seal the faulty vein.
• Endovenous laser ablation (EVLA): Similar principle using laser energy.
• Cyanoacrylate glue (VenaSeal): Medical adhesive injected into the vein to seal it shut. No thermal energy needed, so no tumescent anesthesia required.
• Mechanochemical ablation (ClariVein): Combines mechanical damage to the vein lining with a sclerosing chemical.

All methods have similar efficacy (>90% vein closure rates). The sealed vein is gradually absorbed by the body, and blood reroutes through healthy veins. These are outpatient procedures with rapid recovery.

Amputation is a last resort, but it is sometimes the best option to save a life when infection is uncontrollable, tissue is irreversibly dead, or pain is intractable. Key points:

• The goal is always to preserve as much functional limb as possible
• Partial foot amputations (toe, ray, transmetatarsal) preserve walking ability far better than below-knee amputations
• The decision should involve a multidisciplinary team: vascular surgeon, podiatrist, infectious disease specialist, wound care specialist, and rehabilitation medicine
• Preoperative vascular assessment is essential to ensure healing at the amputation site
• Post-amputation rehabilitation, prosthetics, and psychological support are critical
• A second opinion is always reasonable before irreversible surgery

Despite fears, amputation can be life-saving and life-improving for patients suffering with uncontrollable infection, severe pain, or non-healing wounds. Modern prosthetics and rehabilitation enable many amputees to return to active, independent lives.

After successful H. pylori eradication, peptic ulcer recurrence drops dramatically — from approximately 60–80% per year (without treatment) to less than 5% per year. Key prevention strategies:

• Confirm H. pylori eradication: Test at least 4 weeks after completing treatment. If still positive, retreat with a different regimen guided by susceptibility testing.
• Avoid unnecessary NSAIDs: Use acetaminophen instead when possible. If NSAIDs are needed, use the lowest dose for the shortest time, and add a PPI.
• Stop smoking: Smoking impairs ulcer healing and increases recurrence risk.
• Limit alcohol: Heavy alcohol use delays healing and may increase recurrence.
• Long-term PPI only if needed: Patients who require ongoing NSAID or aspirin therapy, or who have had complicated ulcers (bleeding), may need maintenance PPI therapy. Others should aim to discontinue PPIs once the ulcer has healed.

VLU recurrence rates are 50–70% without ongoing prevention. With consistent compression and lifestyle changes, recurrence can be reduced dramatically:

• Lifelong compression stockings: Class 2 (23–32 mmHg) or Class 3 compression stockings must be worn daily after healing. Replace every 3–6 months as they lose elasticity.
• Leg elevation: Elevate legs above heart level for 30 minutes, 3–4 times daily.
• Exercise: Walking and calf muscle exercises improve venous return. Ankle dorsiflexion exercises (pumping the foot up and down) activate the calf muscle pump.
• Skin care: Keep skin moisturized, treat eczema promptly, avoid trauma to the legs.
• Weight management: Obesity worsens venous hypertension.
• Venous ablation: If not done during treatment, consider ablation of refluxing veins to reduce recurrence.

DFU recurrence rates are approximately 40% within 1 year and up to 65% within 5 years of healing. Prevention requires lifelong vigilance:

• Daily foot inspections: Check all surfaces of both feet every day for redness, blisters, cuts, warmth, or swelling. Use a mirror or ask a family member to check areas you cannot see.
• Therapeutic footwear: Custom-molded shoes and insoles distribute pressure and protect deformed feet. Insurance (including Medicare) often covers diabetic shoes — ask your podiatrist.
• Regular podiatric care: Professional foot exams every 1–3 months for high-risk patients. Nail care and callus removal by a podiatrist — never self-treat calluses with sharp instruments.
• Temperature monitoring: Emerging evidence supports daily foot temperature monitoring using infrared thermometers or smart insoles. A temperature difference of >4°F between corresponding spots on each foot may indicate pre-ulcerative inflammation.
• Blood sugar control: Maintain HbA1c at target (<7% for most patients).
• Smoking cessation: Smoking worsens both neuropathy and vascular disease.

Wound healing is a metabolically demanding process. Adequate nutrition is essential:

• Protein: The building block of tissue repair. Aim for 1.25–1.5 grams of protein per kilogram of body weight daily during active wound healing. Good sources: lean meat, poultry, fish, eggs, dairy, beans, lentils.
• Calories: Healing wounds increase caloric needs by 25–40%. Inadequate calories force the body to break down muscle for energy instead of building new tissue.
• Vitamin C: Essential for collagen synthesis and immune function. Deficiency impairs healing. Found in citrus fruits, berries, peppers, broccoli. Supplementation (250–500 mg daily) is often recommended during active wound healing.
• Zinc: Important for cell division and immune function. Found in meat, shellfish, legumes, nuts. Supplementation (15–40 mg daily) may help in deficient patients, but excessive zinc can impair copper absorption.
• Iron: Needed for oxygen transport. Anemia impairs wound healing. Treat iron deficiency if present.
• Hydration: Dehydrated skin is more susceptible to breakdown. Aim for adequate fluid intake daily.

If you have difficulty eating enough (poor appetite, dental problems, dysphagia), oral nutritional supplements (Ensure, Boost) provide concentrated calories and protein. Ask for a referral to a dietitian for a personalized plan.

Smoking is detrimental to virtually every type of ulcer:

• Peptic ulcers: Smoking impairs ulcer healing and doubles recurrence risk
• Venous ulcers: Smoking delays healing and worsens venous disease
• Arterial ulcers: Smoking is the single most important modifiable risk factor for peripheral artery disease
• Diabetic foot ulcers: Smoking worsens both neuropathy and vascular disease in diabetes
• Pressure injuries: Smoking impairs skin blood flow and delays healing

Quitting smoking is one of the most impactful actions you can take for ulcer healing and prevention. Support options include nicotine replacement therapy (patches, gum, lozenges), prescription medications (varenicline/Chantix, bupropion/Wellbutrin), counseling, and quitlines (1-800-QUIT-NOW). Combining medication with counseling doubles success rates.

Exercise: Regular physical activity improves circulation, blood sugar control, venous return, and overall healing capacity. For venous ulcers, walking and calf exercises are therapeutic. For diabetic patients, supervised exercise improves glycemic control. For bedbound patients, even small movements (ankle pumps, arm exercises) help. Always clear exercise plans with your care team, especially with foot ulcers or arterial disease.

Mental health: Living with a chronic, non-healing wound is psychologically draining. Depression, anxiety, social isolation, and reduced quality of life are common and underrecognized. Pain management is also often inadequate. If you are struggling emotionally, tell your care team — treatment for depression and anxiety can improve wound healing outcomes. Support groups (online and in-person) connect you with others who understand.

Next-generation skin substitutes are moving beyond simple scaffolds to include living cells, growth factors, and three-dimensional structures that more closely mimic natural skin. Stem cell therapies (using bone marrow-derived or adipose-derived stem cells) are being studied for their ability to promote healing in chronic wounds. Several clinical trials are underway, though no stem cell therapy is yet FDA-approved for wound healing.

Smartphone applications and dedicated devices using artificial intelligence can now measure wound size, track healing progress, detect early signs of infection, and alert patients and providers to concerning changes. Technologies like Swift Medical and Tissue Analytics (net Health) are increasingly used in clinical settings. Consumer-facing apps are emerging that allow patients to photograph wounds at home and share them securely with their care team — a form of telemedicine wound monitoring that reduces travel burden and enables earlier intervention.

Chronic wounds often harbor biofilms — organized communities of bacteria encased in a protective slime layer that makes them resistant to antibiotics and the immune system. Biofilms are present in an estimated 60–80% of chronic wounds. New anti-biofilm strategies include: disrupting the biofilm matrix with enzymes (dispersin B), using bacteriophages (viruses that specifically kill bacteria) as an alternative to antibiotics, and novel wound cleansing solutions containing surfactants designed to break down biofilm structure. These approaches are in early clinical trials.

The gut microbiome is increasingly recognized as playing a role in H. pylori treatment success and side effects. Antibiotic regimens for H. pylori eradication substantially disrupt the gut microbiome, contributing to diarrhea and potentially longer-term effects. Research is exploring whether probiotics (specific bacterial strains) taken alongside eradication therapy can improve success rates and reduce side effects. Fecal microbiota analysis may eventually help predict which patients will respond to which regimens. These approaches are investigational.

Japan has the highest gastric cancer screening rate globally, driven by the strong link between H. pylori and gastric cancer. Japan’s aggressive test-and-treat program for H. pylori has led to declining gastric cancer rates. Vonoprazan was developed and first approved in Japan (as Takecab) in 2015, with over a decade of real-world safety and efficacy data. Japanese endoscopists are world leaders in endoscopic hemostasis techniques for bleeding ulcers, including endoscopic submucosal dissection (ESD) for early gastric lesions.

The European Wound Management Association (EWMA) sets standards for wound care practice across Europe. The UK’s NICE guidelines provide some of the most detailed evidence-based recommendations for venous leg ulcer compression therapy. The EVRA trial (early endovenous ablation) was a UK-led landmark study. Germany has a strong tradition of compression therapy and wound care certification. European H. pylori regimens differ from US practice, often with more extensive use of bismuth quadruple therapy and different resistance patterns.

South Korea: Bismuth-based quadruple therapy is a standard first-line H. pylori regimen due to high clarithromycin resistance. South Korea has one of the highest H. pylori prevalence rates globally, with increasing antibiotic resistance driving research into novel eradication strategies.

Latin America: High H. pylori burden with unique resistance patterns (high metronidazole and clarithromycin resistance). Access to advanced wound care therapies (negative pressure, skin substitutes, hyperbaric oxygen) is limited outside major urban centers, creating significant treatment disparities.

• Empiric clarithromycin triple therapy (in high-resistance areas) DE-ADOPTED — Once the universal first-line H. pylori regimen, PPI + clarithromycin + amoxicillin triple therapy is no longer recommended as empiric therapy in regions where clarithromycin resistance exceeds 15%. The ACG 2024 guidelines have moved away from this approach due to declining eradication rates (as low as 63–70% in some US populations). It remains acceptable only when clarithromycin susceptibility has been confirmed by testing.
• Seven-day treatment courses DE-ADOPTED — Older H. pylori guidelines allowed 7-day or 10-day regimens. Current evidence and all major guidelines now mandate 14-day treatment duration for optimal eradication rates. Shorter courses are no longer recommended.
• Highly selective vagotomy (HSV) for duodenal ulcers DE-ADOPTED — Before H. pylori was discovered, surgical vagotomy (cutting the vagus nerve branches to reduce acid secretion) was a standard treatment for refractory duodenal ulcers. With effective acid suppression medications (PPIs) and H. pylori eradication, elective vagotomy is now almost never performed for uncomplicated peptic ulcer disease.
• Sucralfate as primary ulcer therapy DE-ADOPTED — Sucralfate (a mucosal protectant) was once used as a primary treatment for peptic ulcers. While it provided some benefit, it is significantly less effective than PPIs for ulcer healing and has been supplanted. It retains a niche role for stress ulcer prophylaxis in some ICU protocols.
• Ranitidine (Zantac) WITHDRAWN — Ranitidine, once one of the most widely used H2-receptor antagonists for acid suppression and ulcer treatment, was withdrawn from the market globally in 2020 after the FDA determined it contained unacceptable levels of NDMA (N-nitrosodimethylamine), a probable carcinogen. Other H2 blockers (famotidine, cimetidine) remain available and are not affected.

• Wet-to-dry dressings as standard wound care DE-ADOPTED — Wet-to-dry gauze dressings were the default wound management approach for decades. They work by non-selective mechanical debridement as the gauze dries and is pulled off. They are painful, damage healthy tissue, delay healing, and are now considered outdated. Modern moist wound healing with appropriate dressings (foam, alginate, hydrocolloid) has replaced this approach in evidence-based practice. Despite this, wet-to-dry dressings are still used in some settings due to tradition and cost perceptions.
• Topical antiseptics (hydrogen peroxide, Dakin’s solution, povidone-iodine at full strength) for chronic wounds DE-ADOPTED — Full-strength antiseptics applied directly to chronic wounds are cytotoxic to fibroblasts and healing cells, delaying rather than promoting healing. Diluted formulations and modern antimicrobial dressings (silver, medical-grade honey) have replaced direct antiseptic application in evidence-based wound care. Hydrogen peroxide at full strength is no longer recommended for wound irrigation.
• Becaplermin (Regranex) for diabetic foot ulcers FAILED — Becaplermin was the first FDA-approved topical growth factor (PDGF-BB) for diabetic foot ulcers. While it showed modest benefit in initial trials, post-marketing data raised safety concerns about increased cancer risk with repeated use, and the FDA added a black-box warning. Combined with modest efficacy, high cost, and the availability of newer wound therapies (skin substitutes, fish skin grafts), becaplermin has largely fallen out of use.
• Growth hormone therapy for pressure injuries FAILED — Systemic growth hormone was investigated as a treatment to accelerate pressure injury healing. While some small studies showed trends toward improved healing, the potential risks (hyperglycemia, fluid retention, theoretical cancer promotion) and lack of robust evidence from large trials have prevented adoption. Growth hormone is not recommended for routine pressure injury management.

The US Food and Drug Administration (FDA) has approved a broad range of ulcer therapies:

• Vonoprazan (Voquezna): FDA-approved in 2023 as Voquezna Triple Pak (vonoprazan + amoxicillin + clarithromycin) and Voquezna Dual Pak (vonoprazan + amoxicillin) for H. pylori eradication. The first potassium-competitive acid blocker (P-CAB) approved in the US.
• Rifabutin triple therapy (Talicia): FDA-approved in 2019 (rifabutin + amoxicillin + omeprazole) as a first-line option for H. pylori eradication, particularly effective against clarithromycin-resistant strains.
• PPIs: Multiple PPIs are available over-the-counter and by prescription. Generic omeprazole, pantoprazole, and lansoprazole are widely accessible and affordable.
• Advanced wound products: Numerous skin substitutes, biological wound matrices (including Kerecis fish skin grafts, EpiFix dHACM), and negative pressure wound therapy devices are FDA-cleared. Coverage varies by payer and indication.
• Ranitidine (Zantac): Withdrawn from the US market in 2020 due to NDMA contamination. Famotidine remains available as an alternative H2 blocker.

European Medicines Agency (EMA):

• Vonoprazan: As of mid-2026, vonoprazan has not yet received EMA marketing authorization for use in EU member states. European H. pylori management relies on PPI-based regimens, with bismuth quadruple therapy (Pylera — bismuth subcitrate + metronidazole + tetracycline in a single capsule) widely used as first-line or rescue therapy. The Maastricht VI/Florence consensus provides European-specific treatment algorithms.
• PPIs: Widely available across Europe, with omeprazole and pantoprazole available without prescription in many member states.
• Wound care: The European Wound Management Association (EWMA) publishes influential guidelines. Compression therapy standards are generally higher in Europe than in the US, with stronger adherence to multilayer bandaging and early venous intervention.

United Kingdom (NICE/MHRA):

• NICE guidelines on H. pylori (CG184) recommend PPI-based triple therapy with susceptibility-guided antibiotic selection. Bismuth quadruple therapy is a recommended second-line option.
• NICE venous leg ulcer guidelines are among the most detailed globally, recommending early referral for vascular assessment and endovenous ablation within 2 weeks for VLU patients with superficial reflux (informed by the EVRA trial, a UK-led study).
• NICE diabetic foot guidelines mandate urgent referral to a multidisciplinary foot team within 24 hours of a new DFU presentation.
• Ranitidine was withdrawn by the MHRA in line with global action.

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has been at the forefront of ulcer therapy innovation:

• Vonoprazan (Takecab): Approved in Japan since 2015 — more than eight years before US approval. Japan has the most extensive real-world vonoprazan data globally, with the drug widely used for H. pylori eradication, GERD, and ulcer healing. Vonoprazan-based triple therapy is the standard first-line H. pylori regimen in Japan.
• H. pylori screening: Japan has implemented aggressive population-level H. pylori testing and treatment as a gastric cancer prevention strategy, given the country’s historically high gastric cancer rates. This test-and-treat approach has contributed to declining gastric cancer incidence.
• Endoscopy standards: Japanese endoscopists are recognized as world leaders in technique, particularly in endoscopic submucosal dissection (ESD) for early gastric lesions and advanced hemostasis methods.

• Vonoprazan: Not yet approved by Health Canada as of mid-2026. Canadian H. pylori treatment follows the Canadian Association of Gastroenterology (CAG) guidelines, which recommend PPI-based quadruple therapy (bismuth-based or concomitant therapy) as the preferred first-line approach, reflecting high clarithromycin resistance rates in parts of Canada.
• PPIs: Widely available in Canada, with several formulations available without prescription.
• Wound care: Wounds Canada (formerly the Canadian Association of Wound Care) publishes national best practice recommendations for chronic wound management, including DFU, VLU, and pressure injury care. Provincial coverage of advanced wound therapies varies significantly.
• Ranitidine: Withdrawn from the Canadian market in line with global regulatory action.

• Vonoprazan: The Therapeutic Goods Administration (TGA) approved vonoprazan in Australia in 2024 for H. pylori eradication, making Australia one of the first Western countries after the US to approve a P-CAB for this indication. PBS (Pharmaceutical Benefits Scheme) listing determines out-of-pocket cost for patients.
• PPIs: Available over-the-counter and on prescription through the PBS. Omeprazole and esomeprazole are the most commonly dispensed.
• Wound care: Wounds Australia publishes national wound management standards. Australian Wound Management Association guidelines align closely with EWMA and IWGDF recommendations. Compression therapy availability and reimbursement vary by state and territory.
• H. pylori management: The Gastroenterological Society of Australia (GESA) publishes H. pylori treatment guidelines. Australian resistance patterns differ from US and European data, with relatively lower clarithromycin resistance in some regions but rising metronidazole resistance.

• Vonoprazan access: Widely used in Japan since 2015 and recently approved in the US (2023) and Australia (2024), but not yet available in Europe or Canada. This means European and Canadian patients do not currently have access to P-CAB-based H. pylori regimens.
• Bismuth formulations: In Europe, Pylera (a single combination capsule of bismuth subcitrate + metronidazole + tetracycline) simplifies bismuth quadruple therapy. In the US, patients must take bismuth subsalicylate, metronidazole, and tetracycline as separate pills, increasing pill burden.
• Venous ulcer pathways: The UK (via NICE) mandates early vascular referral and ablation for VLU patients with superficial reflux within 2 weeks. No equivalent mandate exists in the US, where access to early ablation is variable and often delayed.
• Wound care reimbursement: Advanced wound therapies (skin substitutes, biologics, hyperbaric oxygen) are more readily reimbursed through US Medicare than in many single-payer systems, which may impose stricter criteria or longer wait times for advanced treatments.
• Antibiotic resistance patterns: H. pylori resistance rates vary substantially by country and region. Clarithromycin resistance is high in Southern Europe, parts of Asia, and increasingly in the US, but lower in Northern Europe. Metronidazole resistance is higher in developing countries. Treatment regimens should always reflect local resistance data.

• University of Utah Health Wound Care Center: Comprehensive wound care and hyperbaric medicine center offering advanced therapies including NPWT, skin substitutes, and hyperbaric oxygen. The vascular surgery program includes limb salvage services for diabetic foot ulcers and arterial disease.
• Intermountain Health: GI endoscopy services and H. pylori clinics across the Wasatch Front. Multiple wound care clinics. Vascular surgery and interventional radiology services.
• Veterans Affairs Salt Lake City Health Care System: Wound care and pressure injury prevention programs. GI services for ulcer diagnosis and treatment. Serves eligible veterans in the Intermountain region.
• Utah podiatry and diabetic foot care: Multiple podiatric medicine practices specializing in diabetic foot care, offloading, and prevention. Ask your primary care physician or endocrinologist for a referral to a podiatrist experienced in diabetic foot management.

If you do not have access to a specialized wound care center, your primary care physician can initiate basic wound care and refer you to the appropriate specialist. Telemedicine wound monitoring is increasingly available and can reduce travel for follow-up visits.

• Wound, Ostomy and Continence Nurses Society (WOCN): wocn.org — Find a certified wound care nurse near you
• Association for the Advancement of Wound Care (AAWC): Patient and provider resources
• American Gastroenterological Association (AGA): gastro.org — Patient information on peptic ulcer disease
• Amputee Coalition: amputee-coalition.org — Support for amputees and those facing amputation decisions
• American Diabetes Association: diabetes.org — Foot care resources for people with diabetes
• National Pressure Injury Advisory Panel (NPIAP): npiap.com — Pressure injury prevention and staging resources

These search terms can help you find current, evidence-based information:

• vonoprazan H. pylori eradication 2024
• ACG H. pylori guidelines 2024
• IWGDF diabetic foot ulcer guidelines 2023
• venous leg ulcer compression EVRA trial
• pressure injury prevention HAPI
• peptic ulcer bleeding endoscopic management
• chronic wound advanced dressings RCT

• Peptic ulcer — an open sore in the lining of the stomach (gastric ulcer) or the first part of the small intestine (duodenal ulcer), caused by acid eroding the protective mucosal barrier.
• H. pylori (Helicobacter pylori) — a spiral-shaped bacterium that infects the stomach lining and is the most common cause of peptic ulcers worldwide. Eradication with antibiotics cures most H. pylori-related ulcers and prevents recurrence.
• NSAID-induced ulcer — an ulcer caused by nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin) which damage the stomach’s protective lining by blocking prostaglandin production. Risk increases with higher doses, longer use, and concurrent factors such as age or corticosteroid use.
• PPI (proton pump inhibitor) — a class of medications (omeprazole, pantoprazole, esomeprazole, lansoprazole) that powerfully reduce stomach acid production by blocking the hydrogen-potassium ATPase enzyme in parietal cells. The cornerstone of peptic ulcer healing.
• Endoscopy — a procedure in which a thin, flexible tube with a camera (endoscope) is passed through the mouth into the stomach and duodenum. Used to directly visualize ulcers, take biopsies, test for H. pylori, and treat active bleeding.
• CLO test (Campylobacter-like organism test) — a rapid urease test performed on a biopsy sample taken during endoscopy. If H. pylori is present, the bacterium’s urease enzyme changes the test indicator color, usually within minutes to hours.

• Diabetic foot ulcer (DFU) — an open wound on the foot of a person with diabetes, typically caused by a combination of peripheral neuropathy (loss of protective sensation), poor circulation, and mechanical stress. DFUs are the leading cause of non-traumatic lower-limb amputation.
• Wagner classification — a grading system for diabetic foot ulcers ranging from grade 0 (at-risk foot, no ulcer) through grade 5 (gangrene of the entire foot). Higher grades indicate deeper tissue involvement and worse prognosis. Grade 0: intact skin at risk; grade 1: superficial ulcer; grade 2: ulcer extending to tendon, capsule, or bone; grade 3: deep ulcer with abscess or osteomyelitis; grade 4: partial foot gangrene; grade 5: whole foot gangrene.
• Offloading — the practice of reducing pressure on a foot ulcer to allow healing. Methods range from specialized footwear and removable walkers to total contact casts. Offloading is one of the most important and most underused interventions in DFU management.
• Total contact cast (TCC) — a custom-molded, minimally padded cast that redistributes weight across the entire sole of the foot rather than concentrating it on the ulcer site. Considered the gold standard for offloading plantar (bottom-of-foot) DFUs, with healing rates significantly higher than removable devices.

• Venous leg ulcer (VLU) — a chronic wound on the lower leg caused by venous insufficiency — the failure of leg vein valves to move blood efficiently back to the heart. Blood pools in the lower legs, causing increased pressure, skin changes, and eventually ulceration. VLUs typically occur on the inner ankle (medial malleolus) area.
• Compression therapy — the application of sustained external pressure to the lower leg using bandages, stockings, or pneumatic devices. Compression counteracts venous hypertension, reduces edema, improves blood flow, and is the single most important treatment for venous leg ulcers. Multi-layer compression bandaging is the standard of care.
• ABI (ankle-brachial index) — a simple, noninvasive test that compares blood pressure at the ankle with blood pressure in the arm. An ABI below 0.9 suggests peripheral arterial disease. The ABI must be measured before applying compression therapy, because compression on a leg with significant arterial disease can be dangerous. An ABI above 0.8 is generally considered safe for compression.

• Pressure injury (pressure ulcer) — damage to the skin and underlying tissue caused by sustained pressure, often over a bony prominence such as the sacrum, heel, or hip. Previously called bedsores or decubitus ulcers. Most common in people with limited mobility.
• NPUAP staging — the National Pressure Injury Advisory Panel (NPIAP, formerly NPUAP) staging system classifies pressure injuries by depth. Stage 1: intact skin with non-blanchable redness. Stage 2: partial-thickness skin loss (blister or shallow open area). Stage 3: full-thickness skin loss (fat visible, but not bone or tendon). Stage 4: full-thickness tissue loss with exposed bone, tendon, or muscle. Unstageable: full-thickness loss obscured by slough or eschar. Deep tissue injury: intact or disrupted skin with persistent non-blanchable deep red, maroon, or purple discoloration.
• Debridement — the removal of dead, damaged, or infected tissue from a wound to promote healing. Methods include sharp (scalpel or scissors), autolytic (moisture-retentive dressings that let the body’s own enzymes break down dead tissue), enzymatic (prescription ointments such as collagenase), mechanical (wet-to-dry dressings, irrigation), and biological (medical-grade maggot therapy). Sharp debridement is the fastest method for heavily necrotic wounds.

• University of Utah Health Wound Care Center — Salt Lake City, UT. Phone: 801-581-2121. Comprehensive wound healing and hyperbaric medicine program. Offers advanced wound therapies including negative pressure wound therapy, bioengineered skin substitutes, and hyperbaric oxygen. The vascular surgery division provides limb salvage and diabetic foot services. Part of an academic health system with access to clinical trials.
• Intermountain Health Wound Care Clinics — Multiple locations along the Wasatch Front and across the Intermountain region. Phone: 801-442-2000. Certified wound care centers offering advanced wound management, compression therapy, and hyperbaric oxygen therapy. Intermountain also operates GI endoscopy centers for peptic ulcer diagnosis and H. pylori treatment.

• Cleveland Clinic Wound Center — Cleveland, OH. Phone: 216-444-2200. One of the largest and most established wound care programs in the United States. Multidisciplinary team including wound care specialists, vascular surgeons, podiatrists, plastic surgeons, and hyperbaric medicine physicians. Nationally recognized for complex wound management, limb salvage, and research in advanced wound healing therapies.
• Johns Hopkins Wound Center — Baltimore, MD. Phone: 410-955-5000. Academic wound care program within the Johns Hopkins Health System. Comprehensive management of chronic and complex wounds including diabetic foot ulcers, venous ulcers, pressure injuries, surgical wound complications, and radiation wounds. Strong research program and access to clinical trials for novel wound therapies.
• Mayo Clinic Wound Care — Rochester, MN. Phone: 507-284-2511. Multidisciplinary wound healing program with vascular surgery, podiatry, plastic surgery, and hyperbaric medicine. One of the highest-volume centers for complex limb salvage and chronic wound management in the US.

• George E. Wahlen VA Medical Center — Salt Lake City, UT. Phone: 801-582-1565. Wound care and pressure injury prevention programs. GI services for ulcer diagnosis and treatment. Spinal cord injury unit with specialized pressure injury prevention. Serves eligible veterans in the Intermountain region.
• VA Limb Preservation Clinics (nationwide) — The Veterans Health Administration operates specialized limb preservation programs at VA medical centers across the country. The VA’s Preservation, Amputation Care, and Treatment (PACT) program is a national initiative to standardize limb preservation. Services include podiatric surgery, vascular intervention, advanced wound care, custom orthotics and prosthetics, and patient education. Contact the VA Health Benefits Hotline at 1-800-827-1000 to confirm eligibility and locate your nearest VA wound care program.

• Wounds Canada — woundscanada.ca. Canada’s leading wound care organization. Provides evidence-based best practice guidelines, patient resources, professional education, and a directory of wound care clinics across Canadian provinces.
• University Health Network (UHN) — Toronto General Hospital Wound Care Centre — Toronto, ON. Phone: 416-340-4800. Comprehensive chronic wound management including diabetic foot, venous leg ulcers, and complex wounds. Part of one of Canada’s largest academic health science centres with access to clinical trials.
• Sunnybrook Health Sciences Centre — Wound Care Program — Toronto, ON. Phone: 416-480-6100. Specialized wound care within a major trauma and rehabilitation centre. Strong pressure injury prevention and spinal cord injury wound care programs.
• McGill University Health Centre (MUHC) — Wound Healing Clinic — Montreal, QC. Phone: 514-934-1934. Academic wound care program with vascular surgery, plastic surgery, and diabetic foot care. Research program in advanced wound therapies.
• Vancouver General Hospital — Wound Care Clinic (UBC) — Vancouver, BC. Phone: 604-875-4111. Provincial referral centre for complex wounds, limb salvage, and vascular intervention. Connected to UBC’s research programs in wound healing.

• European Wound Management Association (EWMA) — ewma.org. The leading European umbrella organization for wound care. Publishes influential guidelines on compression therapy, antimicrobial stewardship in wounds, and wound care economics. Guidance documents are freely available online.
• King’s College Hospital — Diabetic Foot Clinic — London, UK. Phone: +44 20 3299 9000. One of Europe’s leading diabetic foot centres. Multidisciplinary team with vascular surgery, podiatry, orthotics, and wound care. Major contributor to the IWGDF guidelines and the EVRA trial evidence base.
• Charité — Universitätsmedizin Berlin, Centre for Wound Healing — Berlin, Germany. Phone: +49 30 450 50. Leading German academic centre for chronic wound management, compression therapy, and vascular ulcer care. Germany has one of Europe’s strongest traditions in compression therapy and wound care certification.
• University of Tokyo Hospital — Department of Gastroenterology — Tokyo, Japan. Phone: +81 3 3815 5411. World-leading centre for H. pylori management and endoscopic hemostasis techniques. Japan pioneered vonoprazan-based eradication therapy and advanced endoscopic methods including ESD.